Intralesional application of epidermal growth factor in limb-threatening ischemic diabetic foot ulcers

Yanar, Fatih; BAKTIROĞLU, Selçuk; GÜVEN, Erdem; Mirasoglu, Bengusu; TOPALAN, Murat; KILIÇOĞLU, ÖNDER İSMET; DEMİR, Levent; AKTAŞ, ŞAMİL

Intralesional application of epidermal growth factor in limb-threatening ischemic diabetic foot ulcers

Şamil AKTAŞ, (İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Sualtı Hekimliği ve Hiperbarik Tıp Anabilim Dalı, İstanbul, Türkiye)

Selçuk BAKTIROĞLU, (İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Genel Cerrahi Anabilim Dalı, İstanbul, Türkiye)

Levent DEMİR, (Van Bölge Hastanesi, Sualtı ve Hiperbarik Tıp Anabilim Dalı, Van, Türkiye)

ÖNDER İSMET KILIÇOĞLU, (İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Ortopedi ve Travmatoloji Anabilim Dalı, İstanbul, Türkiye)

Murat TOPALAN, (İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Plastik, Rekonstrüktif ve Estetik Cerrahi Anabilim Dalı, İstanbul, Türkiye)

Erdem GÜVEN, (İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Plastik, Rekonstrüktif ve Estetik Cerrahi Anabilim Dalı, İstanbul, Türkiye)

Bengüsu MİRASOĞLU, (İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Sualtı Hekimliği ve Hiperbarik Tıp Anabilim Dalı, İstanbul, Türkiye)

Fatih YANAR (İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Genel Cerrahi Anabilim Dalı, İstanbul, Türkiye)

Acta Orthopaedica et Traumatologica Turcica

1 0

Yıl: 2016 Cilt: 50 Sayı: 3 Sayfa Aralığı: 277 - 283 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

Intralesional application of epidermal growth factor in limb-threatening ischemic diabetic foot ulcers

Öz:

Objective: The intralesional injection of recombinant human epidermal growth factor (EGF-IL), a new therapy, has been claimed to prevent major amputations in advanced diabetic foot lesions. In this study, the efficacy of EGF-IL on advanced diabetic foot ulcers (DFU) was reviewed.Methods: Intralesional 75 ?g EGF application (Heberprot-P® 75, Heber Biotec, Havana, Cuba) to 12 diabetic foot lesions in 11 patients (8 males, 3 females; mean age: 62.2±10.6 years) was evaluated. Most of the patients had undergone revascularization and received hyperbaric oxygen therapy (HBOT) and negative pressure wound therapy (NPWT), along with standard care, but failed to heal. After amputation was offered as the final option, EGF-IL was applied to evaluate its effects.Results: Two patients underwent amputation, while 10 lesions of the remaining 9 patients healed completely.Conclusion: Our results prove that intralesional application of EGF can prevent amputations in advanced diabetic foot cases with an ischemic component. However, evidence in the literature supporting its use remains lacking, and its high cost presents an additional problem. Thus, we believe that intralesional application of EGF should be an option for ischemic wounds only after vascular evaluation (and intervention when possible), HBOT, NPWT, and standard care have proven insufficient.

Anahtar Kelime:

Konular: Cerrahi

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Bibliyografik

Wild S, Roglic G, Green A, Sicree R, King H. Global prev- alence of diabetes: estimates for the year 2000 and projec- tions for 2030. Diabetes Care 2004;27:1047-53.
Satman I, Omer B, Tutuncu Y, Kalaca S, Gedik S, Dinc- cag N, et al. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol 2013;28:169-80.
Satman I, Yilmaz T, Sengül A, Salman S, Salman F, Uygur S, et al. Population-based study of diabetes and risk charac- teristics in Turkey: results of the turkish diabetes epidemi- ology study (TURDEP). Diabetes Care 2002;25:1551-6.
Singh N, Armstrong DG, Lipsky BA. Preventing foot ul- cers in patients with diabetes. JAMA. 2005;293:217-28.
Frykberg RG, Armstrong DG, Giurini J, Edwards A, Kra- vette M, Kravitz S, et al. Diabetic foot disorders: a clinical practice guideline. American College of Foot and Ankle Surgeons. J Foot Ankle Surg 2000;39(5 Suppl):S1-60.
Gesell LB. Hyperbaric oxygen: definition. In: Ge- sell LB (Chair & Editor) Hyperbaric Oxygen Therapy Indications.12th ed. The Hyperbaric Oxygen Therapy Committee Report. Durham, NC: UHMS. p. 4-6.
Abidia A, Laden G, Kuhan G, Johnson BF, Wilkinson AR, Renwick PM, et al. The role of hyperbaric oxygen therapy in ischaemic diabetic lower extremity ulcers: a double- blind randomised-controlled trial. Eur J Vasc Endovasc Surg 2003;25:513-8.
Löndahl M, Katzman P, Nilsson A, Hammarlund C. Hyperbaric oxygen therapy facilitates healing of chron- ic foot ulcers in patients with diabetes. Diabetes Care 2010;33:998-1003.
Faglia E, Favales F, Aldeghi A, Calia P, Quarantiello A, Ori- ani G, et al. Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ul- cer. A randomized study. Diabetes Care 1996;19:1338-43.
Ubbink DT, Westerbos SJ, Evans D, Land L, Vermeulen H. Topical negative pressure for treating chronic wounds. Cochrane Database Syst Rev 2008;3:CD001898.
Armstrong DG, Lavery LA; Diabetic Foot Study Con- sortium. Negative pressure wound therapy after partial diabetic foot amputation: a multicentre, randomised con- trolled trial. Lancet 2005;366:1704-10.
Blume PA, Walters J, Payne W, Ayala J, Lantis J. Compari- son of negative pressure wound therapy using vacuum-as- sisted closure with advanced moist wound therapy in the treatment of diabetic foot ulcers: a multicenter randomized controlled trial. Diabetes Care 2008;31:631-6.
Cohen S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem 1962;237:1555-62.
Nanney LB. Epidermal and dermal effects of epidermal growth factor during wound repair. J Invest Dermatol 1990;94:624-9.
Acosta JB, Savigne W, Valdez C, Franco N, Alba JS, del Rio A, et al. Epidermal growth factor intralesional infiltra- tions can prevent amputation in patients with advanced diabetic foot wounds. Int Wound J 2006;3:232-9.
Al-Delaimy WK, Merchant AT, Rimm EB, Willett WC, Stampfer MJ, Hu FB. Effect of type 2 diabetes and its du- ration on the risk of peripheral arterial disease among men. Am J Med 2004;116:236-40.
Margolis DJ, Jeffcoate W. Epidemiology of foot ulceration and amputation: can global variation be explained? Med Clin North Am 2013;97:791-805.
Rubio JA, Aragón-Sánchez J, Jiménez S, Guadalix G, Al- barracín A, Salido C, et al. Reducing major lower extremity amputations after the introduction of a multidisciplinary team for the diabetic foot. Int J Low Extrem Wounds 2014;13:22-6.
Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al. International prevalence, recognition, and treat- ment of cardiovascular risk factors in outpatients with ath- erothrombosis. JAMA 2006;295:180-9.
Prompers L, Schaper N, Apelqvist J, Edmonds M, Jude E, Mauricio D, et al. Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE Study. Diabetologia 2008;51:747-55.
Moulik PK, Mtonga R, Gill GV. Amputation and mortal- ity in new-onset diabetic foot ulcers stratified by etiology. Diabetes Care 2003;26:491-4.
Hinchliffe RJ, Andros G, Apelqvist J, Bakker K, Friederichs S, Lammer J, et al. A systematic review of the effectiveness of revascularization of the ulcerated foot in patients with diabetes and peripheral arterial disease. Diabetes Metab Res Rev 2012;28 Suppl 1:179-217.
Inan B, Aydin U, Ugurlucan M, Aydin C, Teker ME. Sur- gical treatment of lower limb ischemia in diabetic patients - long-term results. Arch Med Sci 2013;9:1078-82.
Romiti M, Albers M, Brochado-Neto FC, Durazzo AE, Pereira CA, De Luccia N. Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemia. J Vasc Surg 2008;47:975-81.
Albers M, Romiti M, Brochado-Neto FC, De Luccia N, Pereira CA. Meta-analysis of popliteal-to-distal vein bypass grafts for critical ischemia. J Vasc Surg 2006;43:498-503.
Fernández-Montequín JI, Valenzuela-Silva CM, Díaz OG, Savigne W, Sancho-Soutelo N, Rivero-Fernández F, et al. Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo-con- trolled, double-blind study. Int Wound J 2009;6:432-43.
Velazquez W, Valles A, Curbelo W. Impact of epidermal growth factor on the treatment of diabetic foot ulcer. Bio- tecnologia Aplicada 2010;27:136-41.

APA	AKTAŞ Ş, BAKTIROĞLU S, DEMİR L, KILIÇOĞLU Ö, TOPALAN M, GÜVEN E, Mirasoglu B, Yanar F (2016). Intralesional application of epidermal growth factor in limb-threatening ischemic diabetic foot ulcers. , 277 - 283.
Chicago	AKTAŞ ŞAMİL,BAKTIROĞLU Selçuk,DEMİR Levent,KILIÇOĞLU ÖNDER İSMET,TOPALAN Murat,GÜVEN Erdem,Mirasoglu Bengusu,Yanar Fatih Intralesional application of epidermal growth factor in limb-threatening ischemic diabetic foot ulcers. (2016): 277 - 283.
MLA	AKTAŞ ŞAMİL,BAKTIROĞLU Selçuk,DEMİR Levent,KILIÇOĞLU ÖNDER İSMET,TOPALAN Murat,GÜVEN Erdem,Mirasoglu Bengusu,Yanar Fatih Intralesional application of epidermal growth factor in limb-threatening ischemic diabetic foot ulcers. , 2016, ss.277 - 283.
AMA	AKTAŞ Ş,BAKTIROĞLU S,DEMİR L,KILIÇOĞLU Ö,TOPALAN M,GÜVEN E,Mirasoglu B,Yanar F Intralesional application of epidermal growth factor in limb-threatening ischemic diabetic foot ulcers. . 2016; 277 - 283.
Vancouver	AKTAŞ Ş,BAKTIROĞLU S,DEMİR L,KILIÇOĞLU Ö,TOPALAN M,GÜVEN E,Mirasoglu B,Yanar F Intralesional application of epidermal growth factor in limb-threatening ischemic diabetic foot ulcers. . 2016; 277 - 283.
IEEE	AKTAŞ Ş,BAKTIROĞLU S,DEMİR L,KILIÇOĞLU Ö,TOPALAN M,GÜVEN E,Mirasoglu B,Yanar F "Intralesional application of epidermal growth factor in limb-threatening ischemic diabetic foot ulcers." , ss.277 - 283, 2016.
ISNAD	AKTAŞ, ŞAMİL vd. "Intralesional application of epidermal growth factor in limb-threatening ischemic diabetic foot ulcers". (2016), 277-283.

APA	AKTAŞ Ş, BAKTIROĞLU S, DEMİR L, KILIÇOĞLU Ö, TOPALAN M, GÜVEN E, Mirasoglu B, Yanar F (2016). Intralesional application of epidermal growth factor in limb-threatening ischemic diabetic foot ulcers. Acta Orthopaedica et Traumatologica Turcica, 50(3), 277 - 283.
Chicago	AKTAŞ ŞAMİL,BAKTIROĞLU Selçuk,DEMİR Levent,KILIÇOĞLU ÖNDER İSMET,TOPALAN Murat,GÜVEN Erdem,Mirasoglu Bengusu,Yanar Fatih Intralesional application of epidermal growth factor in limb-threatening ischemic diabetic foot ulcers. Acta Orthopaedica et Traumatologica Turcica 50, no.3 (2016): 277 - 283.
MLA	AKTAŞ ŞAMİL,BAKTIROĞLU Selçuk,DEMİR Levent,KILIÇOĞLU ÖNDER İSMET,TOPALAN Murat,GÜVEN Erdem,Mirasoglu Bengusu,Yanar Fatih Intralesional application of epidermal growth factor in limb-threatening ischemic diabetic foot ulcers. Acta Orthopaedica et Traumatologica Turcica, vol.50, no.3, 2016, ss.277 - 283.
AMA	AKTAŞ Ş,BAKTIROĞLU S,DEMİR L,KILIÇOĞLU Ö,TOPALAN M,GÜVEN E,Mirasoglu B,Yanar F Intralesional application of epidermal growth factor in limb-threatening ischemic diabetic foot ulcers. Acta Orthopaedica et Traumatologica Turcica. 2016; 50(3): 277 - 283.
Vancouver	AKTAŞ Ş,BAKTIROĞLU S,DEMİR L,KILIÇOĞLU Ö,TOPALAN M,GÜVEN E,Mirasoglu B,Yanar F Intralesional application of epidermal growth factor in limb-threatening ischemic diabetic foot ulcers. Acta Orthopaedica et Traumatologica Turcica. 2016; 50(3): 277 - 283.
IEEE	AKTAŞ Ş,BAKTIROĞLU S,DEMİR L,KILIÇOĞLU Ö,TOPALAN M,GÜVEN E,Mirasoglu B,Yanar F "Intralesional application of epidermal growth factor in limb-threatening ischemic diabetic foot ulcers." Acta Orthopaedica et Traumatologica Turcica, 50, ss.277 - 283, 2016.
ISNAD	AKTAŞ, ŞAMİL vd. "Intralesional application of epidermal growth factor in limb-threatening ischemic diabetic foot ulcers". Acta Orthopaedica et Traumatologica Turcica 50/3 (2016), 277-283.